2. Search Result
Search Result
Pathways Recommended: Immunology/Inflammation
Results for "

liver inflammation

" in MedChemExpress (MCE) Product Catalog:

64

Inhibitors & Agonists

3

Screening Libraries

2

Biochemical Assay Reagents

3

Peptides

2

Inhibitory Antibodies

12

Natural
Products

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-147041
    Selvigaltin

    GB1211

    		 Galectin Inflammation/Immunology Cancer
    Selvigaltin (GB1211) is an orally active galectin-3 small molecule inhibitor with an IC50 value of 12 nM in rabbits, showing anti-tumor activity. Selvigaltin decreases galectin-3 levels in the liver and reduces biomarkers of liver function (AST, ALT, bilirubin), inflammation (cells foci) and fibrosis (PSR, SHG), as well as decreasing the mRNA and protein expression of several key inflammation and fibrosis biomarkers (IL6, TGFβ3, SNAI2, collagen). Selvigaltin restores T-cell activity and induces less tumors and metastasis .
    Selvigaltin
  • HY-117985B
    Evogliptin tartrate

    DA-1229 tartrate

    		 Dipeptidyl Peptidase Autophagy Metabolic Disease Inflammation/Immunology
    Evogliptin (DA-1229) tartrate is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin tartrate also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin tartrate can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
    Evogliptin tartrate
  • HY-N4063
    Hedragonic acid

    		FXR Inflammation/Immunology
    Hedragonic acid is an oleane-type triterpenoid compound, which can be isolated from the stems and roots of the southern snake vine. Hedragonic acid is a ligand and agonist for FXR. Hedragonic acid protected mice from liver damage caused by acetaminophen overdose and reduced liver inflammation .
    Hedragonic acid
  • HY-122916
    7-Acetyllycopsamine

    		Others Metabolic Disease Inflammation/Immunology
    7-Acetyllycopsamine, a pyrrolizidine alkaloid, is a mild hepatotoxin. 7-Acetyllycopsamine can induce liver inflammation in mice .
    7-Acetyllycopsamine
  • HY-171454
    DA-1241

    		GPR119 Metabolic Disease Inflammation/Immunology
    DA-1241 is a GPR119 agonist. DA-1241 reduces macrophage differentiation through downregulation of NFκB signaling by activating GPR119. DA-1241, alone and in combination with a DPP4 inhibitor, reduces liver inflammation and restores inflammation-related liver gene expression. DA-1241 can be used for the research of metabolic dysfunction-associated steatohepatitis (MASH) .
    DA-1241
  • HY-167643
    Hydroxy tipelukast

    		Drug Metabolite Metabolic Disease Inflammation/Immunology
    Hydroxy tipelukast (Compound MN-002), the metabolite of Compound MN-001, is an orally active phenoxyalkylcarboxylic acid. Hydroxy tipelukast inhibits liver steatosis, lobular inflammation, hepatic ballooning, and hepatic scarring, and reduces liver hydroxyproline levels. Hydroxy tipelukast is promising for research of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) .
    Hydroxy tipelukast
  • HY-146350
    TrxR-IN-4

    		TrxR Cancer
    TrxR-IN-4 (Compound 1b) is a potent inhibitor of TrxR. TrxR-IN-4 induces HepG2 cells apoptosis by activating the endoplasmic reticulum stress (ERS). TrxR-IN-4 improves the CCl4-induced liver damage in vivo by down-regulation of TrxR expression and inflammation level .
    TrxR-IN-4
  • HY-117985
    Evogliptin

    DA-1229

    		 Dipeptidyl Peptidase Autophagy Metabolic Disease Inflammation/Immunology
    Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
    Evogliptin
  • HY-16521
    VX-166

    		Caspase Inflammation/Immunology
    VX-166, a pan caspase inhibitor, can be used for the research of Non- Alcoholic Fatty Liver Disease (NAFLD), nonalcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), and other diseases involving fibrosis, steatosis, or inflammation of the liver .
    VX-166
  • HY-N4217
    Saikosaponin I

    		Others Others
    Saikosaponin I is a triterpene saponin extracted from Bupleurum falcatum L. Saikosaponin can be used to treat fever, inflammation, liver disease, and nephritis .
    Saikosaponin I
  • HY-169192
    BAR-2227

    		FXR Inflammation/Immunology
    BAR-2227 (compound 3a) is a FXR agonist and LIFR inhibitor. BAR-2227 can be used to study liver fibrosis and inflammation .
    BAR-2227
  • HY-N9921
    Antcin A

    		Pyroptosis NOD-like Receptor (NLR) Inflammation/Immunology
    Antcin A is a potent NLRP3 inhibitor that inhibits the assembly and activation of the NLRP3 inflammasome. Antcin A can inhibit Kupffer cell pyroptosis and has liver protective activity. Antcin A can be used to study inflammation, such as non-alcoholic fatty liver disease .
    Antcin A
  • HY-161851
    MDL3

    		Phosphodiesterase (PDE) Metabolic Disease
    MDL3 is a novel inhibitor of PDE4B and PDE5A. MDL3 against liver injury and inflammation and inhibits the pathological remodeling of adipose tissue .
    MDL3
  • HY-155525
    Anti-NASH agent 1

    		PPAR Metabolic Disease Inflammation/Immunology
    Anti-NASH agent 1 (compound 3d)，a derivative of Elafibranor (HY-16737)，is a potent agonist of PPAR-α/δ，targeting to nonalcoholic steatohepatitis (NASH). Anti-NASH agent 1 (3-10 mg/kg; 4 weeks) improves hyperlipidemia，liver fat degeneration and liver inflammation in Methionine-choline deficiency (MCD) induced NASH mice model. Anti-NASH agent 1 shows low liver toxicity and potent liver protection effect .
    Anti-NASH agent 1
  • HY-111179
    ML261

    		Drug Derivative Inflammation/Immunology
    ML261 is a hepatic lipid droplets formation inhibitor with an IC50 value of 69.7 nM. ML261 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and inflammation .
    ML261
  • HY-151932
    FXR agonist 3

    		FXR Inflammation/Immunology
    FXR agonist 3 is an anti-NASH agent, acting by activating FXR. FXR agonist 3 inhibits COL1A1, TGF-β1, α-SMA and TIMP1 expression with anti-fibrogenic activity. FXR agonist 3 significantly reduces liver steatosis and inflammation, improves liver fibrosis level .
    FXR agonist 3
  • HY-B1311
    Proadifen hydrochloride
    1 Publications Verification

    SKF-525A; U-5446; RP-5171

    		 Cytochrome P450 Monoamine Oxidase Bcl-2 Family Survivin PARP Neurological Disease Inflammation/Immunology Cancer
    Proadifen (SKF-525A) hydrochloride is a non-competitive Cytochrome P450 inhibitor with an IC50 value of 19 μM. Proadifen hydrochloride reduces monoamine oxidase A (MAO-A) activity and reverses the antidepressantlike behavioral effect of Imipramine (HY-B1490A) and Desipramine (HY-B1272A) in rats. Proadifen hydrochloride also reduces N, N-dimethyltryptamine (DMT) metabolism in liver microsomes and inhibits N-demethylationand Acridone (HY-W007771) formation. Proadifen hydrochloride augments Lipopolysaccharide (LPS) (HY-D1056)-induced fever and exacerbates Prostaglandin E2 (PGE2) (HY-101952) levels in the rat. Proadifen hydrochloride is promising for research of metabolism-related deseases, ovarian carcinoma, inflammation and dopamine neurons-related deseases .
    Proadifen hydrochloride
  • HY-B1311R
    Proadifen (hydrochloride) (Standard)

    		Cytochrome P450 Monoamine Oxidase Bcl-2 Family Survivin PARP Neurological Disease Inflammation/Immunology Cancer
    Proadifen (hydrochloride) (Standard) is the analytical standard of Proadifen (hydrochloride). This product is intended for research and analytical applications. Proadifen (SKF-525A) hydrochloride is a non-competitive Cytochrome P450 inhibitor with an IC50 value of 19 μM. Proadifen hydrochloride reduces monoamine oxidase A (MAO-A) activity and reverses the antidepressantlike behavioral effect of Imipramine (HY-B1490A) and Desipramine (HY-B1272A) in rats. Proadifen hydrochloride also reduces N, N-dimethyltryptamine (DMT) metabolism in liver microsomes and inhibits N-demethylationand Acridone (HY-W007771) formation. Proadifen hydrochloride augments Lipopolysaccharide (LPS) (HY-D1056)-induced fever and exacerbates Prostaglandin E2 (PGE2) (HY-101952) levels in the rat. Proadifen hydrochloride is promising for research of metabolism-related deseases, ovarian carcinoma, inflammation and dopamine neurons-related deseases [4] .
    Proadifen (hydrochloride) (Standard)
  • HY-128135
    MHY 553

    		PPAR Inflammation/Immunology
    MHY 553 is a PPARα agonist that is effective when taken orally. MHY 553 helps alleviate liver fat accumulation by increasing fatty acid oxidation and reducing inflammation during the aging process. MHY 553 inhibits the accumulation of triglycerides induced by liver X receptor agonists in HepG2 cells. MHY 553 significantly suppresses the expression of inflammatory mRNA in aging rats .
    MHY 553
  • HY-147296
    Omesdafexor

    MET642

    		 FXR Inflammation/Immunology Cancer
    Omesdafexor (MET642) is an oral FXR agonist. Omesdafexor can improve colitis induced by adoptive T cell transfer，promote intestinal antimicrobial function, barrier function and inhibit inflammation .
    Omesdafexor
  • HY-110228
    Metformin-d6 hydrochloride

    1,1-Dimethylbiguanide-d6 hydrochloride

    		 AMPK Autophagy Mitophagy Apoptosis mTOR Cardiovascular Disease Metabolic Disease
    Metformin-d6 hydrochloride is a deuterium labeled Metformin hydrochloride. Metformin hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .
    Metformin-d6 hydrochloride
  • HY-173565
    ACC-IN-1

    		Acetyl-CoA Carboxylase Inflammation/Immunology
    ACC-IN-1 (Compound B1) is an allosteric inhibitor of acetyl-CoA carboxylase (ACC). ACC-IN-1 targets ACC to regulate lipid metabolism, which can improve liver steatosis, inflammation related to non-alcoholic steatohepatitis (NASH) .
    ACC-IN-1
  • HY-173383
    DOPE-DOTA sodium

    1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N- tetraazacyclododecane-N-tetraacetic acid, sodium salt

    		 Biochemical Assay Reagents Inflammation/Immunology Cancer
    DOPE-DOTA sodium is a chelated lipid that serves as a key contrast agent in magnetic resonance imaging (MRI). DOPE-DOTA sodium can be used for cancer, blood-brain barrier disruption, abnormalities such as aneurysms or plaque buildup, inflammation in arthritis, and liver function and lesions study
    DOPE-DOTA sodium
  • HY-B0627
    Metformin
    Maximum Cited Publications
    136 Publications Verification

    1,1-Dimethylbiguanide

    		 AMPK Autophagy Mitophagy Apoptosis mTOR Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, metformin regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .
    Metformin
  • HY-17471A
    Metformin hydrochloride
    Maximum Cited Publications
    136 Publications Verification

    1,1-Dimethylbiguanide hydrochloride

    		 AMPK Autophagy Mitophagy Apoptosis mTOR Cardiovascular Disease Metabolic Disease Cancer
    Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .
    Metformin hydrochloride
  • HY-108022A
    Azemiglitazone potassium

    MSDC-0602K

    		 Insulin Receptor PPAR Metabolic Disease
    Azemiglitazone potassium (MSDC-0602K), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC50 of 18.25 μM . Azemiglitazone potassium modulates the mitochondrial pyruvate carrier (MPC). Azemiglitazone potassium can be used for the research of fatty liver including dysfunctional lipid metabolism, inflammation, and insulin resistance . Azemiglitazone potassium, an insulin sensitizer, improves insulinemia and fatty liver disease in mice, alone and in combination with Liraglutide .
    Azemiglitazone potassium
  • HY-B0627A
    Metformin (glycinate)

    1,1-Dimethylbiguanide (glycinate)

    		 AMPK Autophagy Mitophagy Apoptosis mTOR Cardiovascular Disease Metabolic Disease Cancer
    Metformin (1,1-Dimethylbiguanide) glycinate inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin glycinate also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, metformin glycinate regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .
    Metformin (glycinate)
  • HY-W013215
    Adrenic acid

    cis-7,10,13,16-Docosatetraenoic acid

    		 Endogenous Metabolite Metabolic Disease Inflammation/Immunology
    Adrenic Acid (cis-7,10,13,16-Docosatetraenoic acid) is a naturally polyunsaturated fatty acid in the adrenal gland, brain, kidney, and vasculature. Adrenic Acid can regulate the vascular tone in arteries of the adrenal cortex. Adrenic Acid also is an inflammation enhancer in non-alcoholic fatty liver disease .
    Adrenic acid
  • HY-100438
    Hydronidone

    		Apoptosis Mitochondrial Metabolism Phosphodiesterase (PDE) COX TGF-beta/Smad Inflammation/Immunology Cancer
    Hydronidone is an orally active pyridine derivative. Hydronidone is an inhibitor of phosphodiesterase-4 (PDE4) and cyclo-oxygenase (COX) as well as TGF-β. Hydronidone induces mitochondrial dysfunction and triggers apoptosis. Hydronidone can be used for liver fibrosis, anti-inflammation and anti-cancer study .
    Hydronidone
  • HY-17471AR
    Metformin (hydrochloride) (Standard)

    1,1-Dimethylbiguanide (hydrochloride) (Standard)

    		 AMPK Autophagy Mitophagy Apoptosis mTOR Cardiovascular Disease Metabolic Disease Cancer
    Metformin hydrochloride (Standard) is the analytical standard of Metformin (hydrochloride). This product is intended for research and analytical applications. Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .
    Metformin (hydrochloride) (Standard)
  • HY-157665
    HSD17B13-IN-39

    		17β-HSD Metabolic Disease
    HSD17B13-IN-39 (Compound A) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-39 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH .
    HSD17B13-IN-39
  • HY-157664
    HSD17B13-IN-38

    		17β-HSD Metabolic Disease
    HSD17B13-IN-38 (Compound D) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-38 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH .
    HSD17B13-IN-38
  • HY-153730
    Hedgehog IN-5

    		Hedgehog Inflammation/Immunology
    Hedgehog IN-5 is an orally active small molecule inhibitor of the hedgehog pathway. Hedgehog IN-5 can be used for the research of fibrotic disease .
    Hedgehog IN-5
  • HY-128145
    HSD17B13-IN-41

    		17β-HSD Metabolic Disease
    HSD17B13-IN-41 (Compound C) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-41 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH .
    HSD17B13-IN-41
  • HY-171462
    SMW139

    		P2X Receptor Interleukin Related Neurological Disease Inflammation/Immunology
    SMW139 is a selective allosteric antagonist of P2X7 receptor, with a Ki value of 32 nM for human P2X7R. The half-life of SMW139 in rat liver microsomes is 47 minutes. SMW139 can be used for inflammation, Alzheimer’s disease, multiple sclerosis study .
    SMW139
  • HY-117985A
    Evogliptin hydrochloride

    DA-1229 hydrochloride

    		 Dipeptidyl Peptidase Metabolic Disease Endocrinology
    Evogliptin hydrochloride (DA-1229 hydrochloride) is an orally available DPP4 inhibitor with significant and durable hypoglycemic effects in mouse models. Evogliptin hydrochloride also inhibits the generation of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin hydrochloride can be used in the research of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
    Evogliptin hydrochloride
  • HY-151959
    FXR agonist 4

    		FXR Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC50 value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD) .
    FXR agonist 4
  • HY-N7741
    Isozaluzanin C

    Dehydrozaluzanin C-derivative

    		 Bacterial Infection Inflammation/Immunology
    Isozaluzanin C (Dehydrozaluzanin c-derivative) is an anti-inflammatory agent that can be isolated from Saussurea lappa and has immunomodulatory effects. Isozaluzanin C improves tissue damage (lung, kidney, and liver) and excessive inflammation in mice induced by LPS (HY-D1056) or CRKP infection. Isozaluzanin C can be used in the study of bacterial infections and sepsi .
    Isozaluzanin C
  • HY-121212
    Icosabutate

    		Others Metabolic Disease Inflammation/Immunology
    Icosabutate, an orally active ω-3 polyunsaturated fatty acid, is an aeicosapentaenoic acid (EPA) derivative. Icosabutate overcomes the drawbacks of unmodified EPA for liver targeting and improves insulin sensitivity, hepatic inflammation and fibrosis . Icosabutate is well tolerated, and efficacious in lowering non-high-density lipoprotein cholesterol (non-HDL-C) levels in persistent hypertriglyceridemia .
    Icosabutate
  • HY-P10897
    SjDX5-271

    		Toll-like Receptor (TLR) NF-κB Cardiovascular Disease Inflammation/Immunology
    SjDX5-271 is a small 3 kDa peptide. SjDX5-271 inhibits the TLR4/MyD88/NF-κB signaling pathway. SjDX5-271 induces cell polarization. SjDX5-271 alleviats hepatic inflammation. SjDX5-271 protects mice against liver ischemia-reperfusion injury .
    SjDX5-271
  • HY-120501
    B022
    5+ Cited Publications

    		 NF-κB Inflammation/Immunology
    B022 is a potent and selective NF-κB-inducing kinase (NIK) inhibitor (Ki of 4.2 nM; IC50=15.1 nM). B022 protects liver from toxin-induced inflammation, oxidative stress, and injury . B022 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    B022
  • HY-173504
    Anti-inflammatory agent 101

    		Others Inflammation/Immunology
    Anti-inflammatory agent 101 (Compound C04) is an orally active anti-inflammatory agent. Anti-inflammatory agent 101 has significant anti-lipid accumulation, anti-inflammatory and anti-fibrotic activities. Anti-inflammatory agent 101 works by reducing fatty acid uptake, stimulating fatty acid oxidation and alleviating inflammation. Anti-inflammatory agent 101 can be used in the study of NASH and its related liver fibrosis .
    Anti-inflammatory agent 101
  • HY-143862
    Pparδ agonist 7

    		PPAR Metabolic Disease
    Pparδ agonist 7 is a potent agonist of Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ agonist 7 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2019105234A1, compound TM4) .
    Pparδ agonist 7
  • HY-143863
    PPARδ agonist 8

    		PPAR Metabolic Disease
    Pparδ agonist 8 is a potent agonist of Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ agonist 8 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2021169769A1, compound TM2) .
    PPARδ agonist 8
  • HY-144549
    LXR agonist 1

    		LXR Cardiovascular Disease
    LXR (Liver X receptor) agonist 1 is potent LXR agonist with AC50s of 1.5 nM and 12 nM for LXR-α and LXR-β, respectively. LXR agonist 1 has the potential for the research of atherosclerosis .
    LXR agonist 1
  • HY-N6804
    Diammonium Glycyrrhizinate

    		NF-κB Reactive Oxygen Species (ROS) Inflammation/Immunology Cancer
    Diammonium glycyrrhizinate is a substance that can be extracted and purified from a traditional Chinese medicinal herb. Diammonium glycyrrhizinate has anti-inflammatory effect, resistance to biologic oxidation, membranous protection and a weak steroidal action. Diammonium glycyrrhizinate exerts protective effect by downregulating inflammation cytokines, suppressing the NF-κB pathway, and restoring superoxide dismutase. Diammonium glycyrrhizinate can be used as a hepatic protector and can therefore be studied in research for most liver diseases .
    Diammonium Glycyrrhizinate
  • HY-117985S
    Evogliptin-d9

    DA-1229-d9

    		 Isotope-Labeled Compounds Autophagy Dipeptidyl Peptidase Metabolic Disease Inflammation/Immunology
    Evogliptin-d9 (DA-1229-d9) is deuterium labeled Evogliptin. Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
    Evogliptin-d9
  • HY-W011641
    (±)-Naringenin
    3 Publications Verification

    		 Potassium Channel Toll-like Receptor (TLR) NF-κB Apoptosis Caspase Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    (±)-Naringenin is an orally available anti-inflammatory agent that can regulate both acute and chronic inflammation responses, while also showing antioxidant, neuroprotective, liver-protective, and anti-cancer effects. (±)-Naringenin promotes vasodilation in endothelial cells by activating BKCa channels in muscle cells. It also exerts protective effects against experimental colitis by inhibiting Toll-like receptor 4/NF-κB signaling, making it useful in studies related to sepsis, fulminant hepatitis, fibrosis, and cancer research .
    (±)-Naringenin
  • HY-N6871
    Abietic acid

    		Bacterial IKK Ferroptosis Infection Metabolic Disease Inflammation/Immunology Cancer
    Abietic acid, an orally active diterpene isolated from Colophony, displays significant anti-proliferative, anti-inflammatory, anti-obesity effect, bacteriostatic, cell cycle arresting and pro-apoptotic activities. Abietic acid inhibits lipoxygenase activity for allergy. Abietic acid enhances cell migration and tube formation in HUVECs. Abietic acid induces significant angiogenic potential, which is associated with upregulation of extracellular signal-regulated kinase (ERK) and p38 expression. Abietic acid attenuates sepsis-induced lung injury by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway to inhibit M1 macrophage polarization. Abietic acid exhibits a positive effect against liver injury by attenuating inflammation and ferroptosis. Abietic acid shows accelerated wound closure in a mouse model of cutaneous wounds. Abietic acid significantly reduces the proliferation and growth of NSCLC cells by IKKβ inhibition.Additionally, Abietic acid ameliorates psoriasis-like inflammation and modulates gut microbiota in mice. Abietic acid is promising for research in non-small-cell lung cancer (NSCLC), liver injury-related deseases and psoriasis .
    Abietic acid
  • HY-145581
    Mitiperstat

    AZD4831

    		 Glutathione Peroxidase Cytochrome P450 Cardiovascular Disease Inflammation/Immunology
    Mitiperstat (AZD4831) is an effective oral inhibitor of myeloperoxidase (MPO). Mitiperstat inhibits MPO and thyroid peroxidase (TPO) with IC50s of 1.5 nM and 0.69 μM. Mitiperstat exhibits a weak inhibitory activity against CYP3A4 with an IC50 of 6 μM. Mitiperstat can reduce inflammation and improve microvascular function, and it can be used in studies related to heart failure, preserved or mildly reduced ejection fraction, non-alcoholic fatty liver disease, and chronic obstructive pulmonary disease .
    Mitiperstat

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: